Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc. announced today that it has raised a $150 million Series B financing to support the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness in children and young adults. The financing was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments. Alkeus also announced today that Joshua Boger, Ph.D., a biotech industry pioneer and the founder of Vertex Pharmaceuticals, has joined Alkeus as Executive Chairman.

Learn More

Alkeus Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc. a late-stage biopharmaceutical company developing a novel treatment for Stargardt disease and geographic atrophy secondary to age-related macular degeneration, today announced that Leonide Saad, Chief Executive Officer of Alkeus Pharmaceuticals, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 1 at 4:45pm Eastern Time.

Learn More